Identification of non-HLA antibodies in ventricular assist device recipients

Identification of non-HLA antibodies in ventricular assist device recipients

Автор: Salisch Sandy Von, Dieterlen Maja-Theresa, Garbade Jens, Klein Sara, Dhein Stefan, Mohr Friedrich W., Bittner Hartmuth B., Barten Markus J.

Журнал: Cardiometry @cardiometry

Рубрика: Original research

Статья в выпуске: 3, 2013 года.

Бесплатный доступ

Aims Recipients of ventricular assist devices (VADR) have a higher incidence to develop antibodies (Abs) against human leukocyte antigens (HLA). Non-HLA antibodies like major histocompatibility complex class I-related chain A (MICA) and autoantibodies against angiotensin type 1 receptor (AT1R) and endothelin receptor A (ETAR) are also implicated in the pathogenesis of acute rejection and allograft vasculopathy. We monitored non-HLA- and HLA-Abs in VADR up to one year after implantation. Materials and methods Sera of 56 VADR (54.1±12.8 years old, 50 men) were analyzed for Abs against HLA-, MICA-, AT1R- and ETAR several times over one year after implantation using ELISA and Luminex xMAP technology. Blood transfusions, gender and age were reviewed. Results Sera of 56 VADR (54.1±12.8 years old, 50 men) were analyzed for Abs against HLA-, MICA-, AT1R- and ETAR several times over one year after implantation using ELISA and Luminex xMAP technology. Blood transfusions, gender and age were reviewed. Conclusion Beside HLA- and MICA-Abs, VADR showed high titres of Abs against AT1R or ETAR, which underlines the necessity for monitoring non-HLA antibodies in VADR prior heart transplantation.

Еще

At1r, etar, hla-antibodies, non-hla antibodies, transplantation, ventricular assist device

Короткий адрес: https://sciup.org/148308746

IDR: 148308746

Список литературы Identification of non-HLA antibodies in ventricular assist device recipients

  • Erren M, Schluter B, Fobker M, Plenz G, Baba H,Willeke P, Kwiotek R, Junker R, Assmann G, Scheld HH, Deng MC. Immunologic effects of implantation of left ventricular assist devices. Transplant Proc. 2001;33:1965-1968
  • Gonzalez-Stawinski GV, Cook DJ, Chang AS, Banbury MK, Navia JL, Hoercher K, Lober C, Atik FA, Taylor DO, Yamani MH, Young JB, Starling RC, Smedira NG. Ventricular assist devices and aggressive immunosuppression: Looking beyond overall survival. J Heart Lung Transplant. 2006;25:613-618
  • Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, Flannery M, Mancini D, Rose EA, Edwards NM, Oz MC, Itescu S. Activation-induced t-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet. 1999;354:550-555
  • Itescu S, Ankersmit JH, Kocher AA, Schuster MD. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis. 2000;43:67-80
  • Itescu S, Schuster M, Burke E, Ankersmit J, Kocher A, Deng M, John R, Lietz K. Immunobiologic consequences of assist devices. Cardiol Clin. 2003;21:119-133, ix-x
  • Bhimaraj A, Taylor DO. How to deal with presensitized candidates for heart transplantation? Current opinion in organ transplantation. 2011;16:529-535
  • Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ Transplantation. Transplantation. 2008;86:1019-1025
  • Dragun D, Hegner B. Non-hla antibodies post-transplantation: Clinical relevance and treatment in solid organ transplantation. Contributions to nephrology. 2009;162:129-139
  • Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, Naim M, Wang Q, Mirocha J, Kahwaji J, Vo AA, Jordan SC, Dragun D. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor hla antibody negative patients. Transplantation.90:1473-1477
  • Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H, Lachmann N, Hetzer R, Dragun D. Non-hla antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart Transplantation. Transplantation. 2012;94:919-924
  • Barten et al. Non-HLA Antibody Screening after Heart Transplantation Identifies High Risk for Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation 2012; 31:107.
  • Kauke et al. Anti-mica antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant. 2009;28:305-311
  • Zou et al. Mica is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum Immunol. 2002;63:30-39
  • Riemekasten et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis.70:530-536
  • Pagani FD, Dyke DB, Wright S, Cody R, Aaronson KD. Development of anti-major histocompatibility complex class i or ii antibodies following left ventricular assist device implantation: Effects on subsequent allograft rejection and survival. J Heart Lung Transplant. 2001;20:646-653
  • Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin at 1 receptor. J Clin Invest. 1999;103:945-952
  • Freudenberger RS, Tawfik I, Shinnar M, Pendergast T. Panel-reactive screening and treatment practices following bridge to transplantation ventricular assist device placement. Transplant Proc. 2009;41:1813-1815
  • George I, Colley P, Russo MJ, Martens TP, Burke E, Oz MC, Deng MC, Mancini DM, Naka Y. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg. 2008; 135:1372-1379
  • Gonzalez-Stawinski GV, Atik FA, McCarthy PM, Roselli EE, Hoercher K, Navia JL, Smedira NG, Starling RC, Young JB, Cook DJ. Early and late rejection and hla sensitization at the time of heart transplantation in patients bridged with left ventricular assist devices. Transplant Proc. 2005;37:1349-1351
  • Coppage M, Baker M, Fialkow L, Meehan D, Gettings K, Chen L, Massey HT, Blumberg N. Lack of significant de novo hla allosensitization in ventricular assist device recipients transfused with leukoreduced, abo identical blood products. Hum Immunol. 2009;70:413-416
  • Schuster M, Kocher A, John R, Hoffman M, Ankersmit J, Lietz K, Edwards N, Oz M, Itescu S. B-cell activation and allosensitization after left ventricular assist device implantation is due to t-cell activation and cd40 ligand expression. Hum Immunol. 2002;63:211-220
  • Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications. The Annals of thoracic surgery. 2003;75:S58-65
  • Drakos SG, Kfoury AG, Kotter JR, Reid BB, Clayson SE, Selzman CH, Stehlik J, Fisher PW, Merida M, 3rd, Eckels DD, Brunisholz K, Horne BD, Stoker S, Li DY, Renlund DG. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant. 2009;28:838-842
  • Drakos SG, Kfoury AG, Long JW, Stringham JC, Fuller TC, Nelson KE, Campbell BK, Gilbert EM, Renlund DG. Low-dose prophylactic intravenous immunoglobulin does not prevent hla sensitization in left ventricular assist device recipients. The Annals of thoracic surgery. 2006;82:889-893
  • Drakos SG, Stringham JC, Long JW, Gilbert EM, Fuller TC, Campbell BK, Horne BD, Hagan ME, Nelson KE, Lindblom JM, Meldrum PA, Carlson JF, Moore SA, Kfoury AG, Renlund DG. Prevalence and risks of allosensitization in heartmate left ventricular assist device recipients: The impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg. 2007;133:1612-1619
  • McKenna DH, Jr., Eastlund T, Segall M, Noreen HJ, Park S. Hla alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant. 2002;21:1218-1224
  • Yousufuddin M, Cook DJ, Starling RC, Abdo A, Paul P, Tuzcu EM, Ratliff NB, McCarthy PM, Young JB, Yamani MH. Angiotensin ii receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol. 2004;43:1565-1573
  • Yousufuddin M, Haji S, Starling RC, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, Saad Y, Karnik SS, Wang D, McCarthy PM, Young JB, Yamani MH. Cardiac angiotensin ii receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J. 2004;25:377-385
  • Yousufuddin M, Yamani MH. The renin-angiotensin hypothesis for the pathogenesis of cardiac allograft vasculopathy. Int J Cardiol. 2004;95:123-127
  • Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and Natural Killer Cells possess a functional renin-angiotensin System: Further mechanisms of angiotensin II-induced inflammation. Journal of American Society of Nephrology. 2007; 18:1093-1102.
  • Silva-Filho JL, Souza MC, Henriques MG, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA. At1 receptor-mediated angiotensin ii activation and chemotaxis of t lymphocytes. Mol Immunol.48:1835-1843
  • Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: Preeclampsia and beyond. Expert review of clinical immunology. 2011;7:659-674
  • Dragun D. The role of angiotensin ii type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatr Nephrol. 2007;22:911-914
  • Suarez-Alvarez et al. The relationship of anti-mica antibodies and mica expression with heart allograft rejection. Am J Transplant. 2007;7:1842-1848
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp